Cost-effectiveness Analysis of Infant Pneumococcal Vaccination with PHiD-CV in Korea

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2017 Nov 9

PMID 29115905

Citations 7

Authors

Xu-Hao Zhang

Oscar Leeuwenkamp

Kyu-Bin Oh

Young Eun Lee

Chul-Min Kim

Affiliations

Soon will be listed here.

Abstract

Background: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are included in the National Immunization Program for infants in Korea. This study aimed to evaluate the cost-effectiveness of the 3+1 schedule of PHiD-CV versus that of PCV-13 for National Immunization Program in Korea.

Methods: A published Markov model was adapted to evaluate the cost-effectiveness of vaccinating the 2012 birth cohort with PHiD-CV vs. PCV-13 from the Korean government perspective over 10 y. Best available published data were used for epidemiology, vaccine efficacy and disutilities. Data on incidence and direct medical costs were taken from the national insurance claims database. Sensitivity analyses were conducted to explore the robustness of the results.

Results: PHiD-CV was projected to prevent an additional 195,262 cases of pneumococcal diseases and NTHi-related diseases vs. PCV-13, with a substantially greater reduction in NTHi-related AOM and a comparable reduction in IPD and community-acquired pneumonia. Parity-priced PHiD-CV generated a health gain of about 844 quality-adjusted life years and a total cost-saving of approximately 4 million United States Dollars (USD) over 10 y. 93% of probabilistic simulations found PHiD-CV 3+1 to be the dominant vaccine option.

Conclusion: Compared to PCV-13, PHiD-CV was projected to provide similar prevention against IPD and community-acquired pneumonia but would prevent more cases of AOM. Parity-priced PHiD-CV was anticipated to generate substantial cost-savings and health benefits vs. PCV-13 in Korea.

Citing Articles

Economic Burden of Otitis Media Globally and an Overview of the Current Scenario to Alleviate the Disease Burden: A Systematic Review.

Bhatia R, Chauhan A, Rana M, Kaur K, Pradhan P, Singh M Int Arch Otorhinolaryngol. 2024; 28(3):e552-e558.

PMID: 38974618 PMC: 11226269. DOI: 10.1055/s-0043-1767802.

Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination: a systematic review.

Scheffer M, Coffeng L, OMahony J Int J Technol Assess Health Care. 2023; 39(1):e42.

PMID: 37435736 PMC: 11570002. DOI: 10.1017/S0266462323000351.

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.

Mohanty S, Hu T, Yang G, Khan T, Owusu-Edusei K, Sukarom I Hum Vaccin Immunother. 2022; 18(5):2046433.

PMID: 35420975 PMC: 9196648. DOI: 10.1080/21645515.2022.2046433.

Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia.

Suwantika A, Zakiyah N, Abdulah R, Sitohang V, Tandy G, Anartati A J Environ Public Health. 2021; 2021:7494965.

PMID: 33995536 PMC: 8096558. DOI: 10.1155/2021/7494965.

Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable protein D conjugate vaccine for children in Taiwan.

Lu C, Chung C, Huang L, Kruger E, Tan S, Zhang X Cost Eff Resour Alloc. 2020; 18:30.

PMID: 32874139 PMC: 7456386. DOI: 10.1186/s12962-020-00225-9.

References

Lee J, Cho H, Kim K, Kim C, Kim D, Kim K . Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): a retrospective multicenter study. J Korean Med Sci. 2011; 26(2):174-83. PMC: 3030999. DOI: 10.3346/jkms.2011.26.2.174. View

Moore M, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett N . Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3):301-9. PMC: 4876855. DOI: 10.1016/S1473-3099(14)71081-3. View

Domingues C, Verani J, Montenegro Renoiner E, Brandileone M, Flannery B, De Oliveira L . Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014; 2(6):464-71. PMC: 9003592. DOI: 10.1016/S2213-2600(14)70060-8. View

McIntosh E, Conway P, Willingham J, Hollingsworth R, Lloyd A . Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine. 2005; 23(14):1739-45. DOI: 10.1016/j.vaccine.2004.08.051. View

Jokinen J, Palmu A, Kilpi T . Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis. 2012; 55(12):1673-6. DOI: 10.1093/cid/cis799. View

Sohn H, Suh D, Jang E, Kwon J . Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea. J Manag Care Pharm. 2010; 16(1):32-45. PMC: 10437513. DOI: 10.18553/jmcp.2010.16.1.32. View

Choi E, Kim K, Kim Y, Kim J, Park S, Lee H . Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea. Korean J Pediatr. 2011; 54(4):146-51. PMC: 3127147. DOI: 10.3345/kjp.2011.54.4.146. View

Palmu A, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T . Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2013; 14(3):205-12. DOI: 10.1016/S1473-3099(13)70338-4. View

Robberstad B, Frostad C, Akselsen P, Kvaerner K, Berstad A . Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011; 29(47):8564-74. DOI: 10.1016/j.vaccine.2011.09.025. View

10.

Shiragami M, Mizukami A, Leeuwenkamp O, Mrkvan T, Delgleize E, Kurono Y . Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children. Infect Dis Ther. 2014; . PMC: 4363214. DOI: 10.1007/s40121-014-0053-7. View

11.

De Wals P, Black S, Borrow R, Pearce D . Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin Ther. 2009; 31(10):2152-69. DOI: 10.1016/j.clinthera.2009.10.014. View

12.

Kaur R, Czup K, Casey J, E Pichichero M . Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis. 2014; 14:640. PMC: 4264249. DOI: 10.1186/s12879-014-0640-y. View

13.

Hausdorff W, Feikin D, Klugman K . Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5(2):83-93. DOI: 10.1016/S1473-3099(05)01280-6. View

14.

OBrien K, Shaw J, Weatherholtz R, Reid R, Watt J, Croll J . Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. Am J Epidemiol. 2004; 160(3):270-8. DOI: 10.1093/aje/kwh191. View

15.

Bennett J, Sumner 2nd W, Downs S, Jaffe D . Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000; 154(1):43-8. View

16.

Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E . Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006; 367(9512):740-8. DOI: 10.1016/S0140-6736(06)68304-9. View

17.

Morrow A, De Wals P, Petit G, Guay M, Erickson L . The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2008; 18(2):121-7. PMC: 2533542. DOI: 10.1155/2007/713576. View

18.

Casey J, Kaur R, Friedel V, E Pichichero M . Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatr Infect Dis J. 2013; 32(8):805-809. PMC: 3755474. DOI: 10.1097/INF.0b013e31828d9acc. View

19.

Wiertsema S, Kirkham L, Corscadden K, Mowe E, Bowman J, Jacoby P . Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Vaccine. 2011; 29(32):5163-70. DOI: 10.1016/j.vaccine.2011.05.035. View

20.

Murphy T . Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis. 2003; 16(2):129-34. DOI: 10.1097/00001432-200304000-00009. View